Hypoalbuminemia as a Prognostic Indicator in MGUS: Biological and Clinical Context

Overview

Hypoalbuminemia (serum albumin ≤3.5 g/dL) at MGUS diagnosis is associated with increased risk of progression to multiple myeloma or related disorders. This biomarker likely reflects an integrative host-related phenotype encompassing inflammation, aging, organ dysfunction, and nutritional status rather than a plasma cell–specific marker.

Background

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with variable risk of progression to multiple myeloma. Serum albumin, a negative acute-phase reactant, is influenced by systemic inflammation, hepatic function, and nutritional status, factors particularly relevant in the older adult population where MGUS predominates. Prior studies have linked hypoalbuminemia with frailty, comorbidity, and mortality in oncologic and geriatric populations. Understanding albumin's role as a host-related biomarker may refine risk stratification beyond clonal plasma cell parameters.

Data Highlights

Key Findings

• Serum albumin ≤3.5 g/dL at MGUS diagnosis correlates with increased progression risk to myeloma or related disorders.
• Hypoalbuminemia reflects systemic inflammation, biological aging, organ dysfunction, and nutritional status rather than plasma cell burden alone.
• Older patients with hypoalbuminemia exhibit higher creatinine and lower hemoglobin, consistent with comorbidities like chronic kidney disease and anemia of inflammation.
• Biological non-specificity of albumin does not negate its prognostic value; it may capture host–clonal interactions influencing disease evolution.
• Study limitations include reliance on a single baseline albumin measurement and lack of longitudinal or correlative bone marrow microenvironment data.
• Findings require validation in independent cohorts due to limited progression events and retrospective single-center design.

Clinical Implications

Serum albumin measurement at MGUS diagnosis can serve as a readily available integrative biomarker reflecting host vulnerability and may enhance risk stratification when combined with clonal parameters. Clinicians should interpret hypoalbuminemia in the context of systemic inflammation, comorbidities, and frailty, recognizing its potential to identify patients at higher risk for progression. Longitudinal monitoring of albumin and comprehensive clinical assessment are recommended to distinguish transient from persistent hypoalbuminemia.

Conclusion

Hypoalbuminemia in MGUS patients represents a nonspecific but prognostically relevant host biomarker that integrates systemic and biological aging factors influencing disease progression. Further prospective studies with longitudinal albumin assessments and microenvironmental correlations are needed to validate and clarify its mechanistic role.

References

1. Alejo et al. 2023 -- Prognostic Role of Hypoalbuminemia in MGUS
2. Clinical Reviews 2022 -- Serum Albumin as a Negative Acute-Phase Reactant
3. Geriatric Oncology Studies 2021 -- Hypoalbuminemia and Frailty Correlations